Serum osteocalcin (ng/ml) · patients with primary biliary cirrhosis.
1 finding from 1 review
The urinary amino telopeptides of collagen I (NTx) (nmol bone collagen equivalents /mmol creatinine) · patients with primary biliary cirrhosis.
1 finding from 1 review
All‐cause mortality · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Fracture · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes fractures compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Mean change in BMD of the lumbar spine · women with primary biliary cirrhosis.
1 finding from 1 review
Change in % of proximal femur bone mineral density (BMD) per year (g/cm2 year‐1) · women with primary biliary cirrhosis.
1 finding from 1 review
Liver morbidity · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes liver‐related morbidity compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Bilirubin (µmol/L) · women with primary biliary cirrhosis.
1 finding from 1 review
Serious adverse events (excluding deaths) at 26 weeks · adult patients after liver transplantation.
1 finding from 1 review
Non‐serious adverse events (range 2–10 months) · adult patients after liver transplantation.
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether methionine and supportive treatment changes mortality compared with supportive treatment (very low certainty).
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
It is very uncertain whether standard intravenous acetylcysteine regimen (20.5 hour) changes hepatotoxicity compared with shorter intravenous acetylcysteine regimen (12 hour) (very low certainty).
1 finding from 1 review
Vomiting, retching, or antiemetics from 0‐2 hours · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics from 0‐2 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
Vomiting, retching, or antiemetics 0‐12 hours · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics 0‐12 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
Anaphylactoid symptoms · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower anaphylactoid symptoms compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nausea · people with paracetamol (acetaminophen) overdose
It is very uncertain whether oral changes nausea compared with intravenous acetylcysteine (very low certainty).
1 finding from 1 review
Vomiting · people with paracetamol (acetaminophen) overdose
It is very uncertain whether oral changes vomiting compared with intravenous acetylcysteine (very low certainty).
1 finding from 1 review